Clinical Decision Summary Patients and clinicians weighing Mounjaro versus retatrutide face a choice between an approved, commercially accessible drug with 72-week phase 3 data and an investigational agent with 48-week phase 2 data that shows numerically superior weight loss but substantially higher GI discontinuation rates
For many individuals, insurance coverage alone does not eliminate the financial barriers associated with these medications, particularly for those enrolled in high-deductible or specialty-tier health plans
How overweight do I need to be to start taking weight loss injections
Alternative timing for people who cannot dose in the morning If morning dosing is not possible, the next best option is taking drops at least 2 hours after your last meal, ideally in the evening before bed
Despite the benefits observed in adequate glycemic control in reducing microvascular events the results are controversial in regard to atherosclerotic disease [17]
Hepatology 2023;78:272-283
.png)
